29
Jan 2019
Breast cancer ‘invasion’ protein identified
Researchers at Cardiff University have identified a protein which allows the ‘growth, spread and invasion’ of aggressive breast cancer cells, and now plan to study ways to target the protein (named LYN) in improved cancer treatments.
Currently, 11,000 people are killed by breast cancer in the UK and there are around 150 new cases diagnosed each day.
Scientists at Cardiff University’s European Cancer Stem Cell Research Institute looked at what drives an aggressive strain of breast cancer, known as triple negative.
The strain occurs in around 15 per cent of cases and is currently resistant to hormone therapy.
Researcher Professor Matt Smalley, said “We looked at a protein called LYN, which is involved in keeping cells alive and allowing them to divide, and found that it was no longer properly controlled in aggressive breast cancer cells and could drive the cancer cell growth, spread and invasion.”
The next stage of the plan is to begin looking into how treatments for breast cancer can be adapted to suit patients with increased levels of LYN.
Chadwick Lawrence’s specialist team of clinical negligence lawyers have years of experience in medical negligence claims, providing support and guidance after life-changing events. Not only do we represent clients in Yorkshire, but because of our reputation we also represent clients nationally.
If you believe that you or a relative may have been injured as a result of clinical/medical negligence, please call for free legal advice from our medical negligence solicitors on the freephone number below.
Posted by Karen Motley, Clinical Negligence Department, Chadwick Lawrence LLP (tonymay@chadlaw.co.uk ), medical negligence lawyers and clinical negligence solicitors in Huddersfield, Leeds, Wakefield and Halifax, West Yorkshire.
Freephone : 0800 304 738
- Like this ? Share with friends